PPA
OREX

Parametric Portfolio Associates’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Parametric Portfolio Associates’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,388
Closed -$13K – 4071
2016
Q1 		$13K Sell
2,388
-1,795
-43% -$23.3K ﹤0.01% 3961
2015
Q4 		$72K Sell
4,183
-4,841
-54% -$115K ﹤0.01% 3894
2015
Q3 		$190K Buy
9,024
+2,915
+48% +$99.9K ﹤0.01% 3103
2015
Q2 		$302K Buy
6,109
+50
+0.8% +$2.99K ﹤0.01% 3571
2015
Q1 		$474K Sell
6,059
-6
-0.1% -$372 ﹤0.01% 3296
2014
Q4 		$368K Sell
6,065
-287
-5% -$14.4K ﹤0.01% 3437
2014
Q3 		$271K Sell
6,352
-334
-5% -$17.9K ﹤0.01% 3508
2014
Q2 		$413K Buy
6,686
+535
+9% +$31.1K ﹤0.01% 3323
2014
Q1 		$400K Buy
6,151
+1,748
+40% +$118K ﹤0.01% 3299
2013
Q4 		$248K Sell
4,403
-84
-2% -$4.72K ﹤0.01% 3520
2013
Q3 		$275K Buy
4,487
+331
+8% +$22.4K ﹤0.01% 3441
2013
Q2 		$243K Buy
+4,156
New +$256K ﹤0.01% 3382

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Parametric Portfolio Associates's OREX Position: Q2 2016 in Review

Parametric Portfolio Associates sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 2,388 shares — an estimated $13K sold.

Parametric Portfolio Associates first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $474K in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

  • Parametric Portfolio Associates reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Parametric Portfolio Associates sold 2,388 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $13K.
  • Parametric Portfolio Associates first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
  • Parametric Portfolio Associates's Orexigen Therapeutics, Inc. position peaked at $474K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Parametric Portfolio Associates's 13F filing for Q2 2016, filed 12 Aug 2016.